Suzhou Zelgen Biopharmaceuticals Co Ltd Working Capital to Net Assets Ratio
Suzhou Zelgen Biopharmaceuticals Co Ltd working capital to net assets ratio. Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) has a Working Capital to Net Assets ratio of 100.2% as of September 2025. Working capital of CN¥1.15 Billion (current assets of CN¥2.51 Billion minus current liabilities of CN¥1.35 Billion) is measured against net assets of CN¥1.15 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Suzhou Zelgen Biopharmaceuticals Co Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Suzhou Zelgen Biopharmaceuticals Co Ltd (2016–2024)
Working capital to net assets ratio of Suzhou Zelgen Biopharmaceuticals Co Ltd from 2016 to 2024. This chart shows how Suzhou Zelgen Biopharmaceuticals Co Ltd's Working Capital to Net Assets ratio has evolved across 9 annual periods from 2016 to 2024. As of September 2025, the ratio stands at 100.2%, reflecting working capital of CN¥1.15 Billion against net assets of CN¥1.15 Billion CNY. See 688266 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Suzhou Zelgen Biopharmaceuticals Co Ltd Working Capital to Net Assets Ratio by Year (2016–2024)
Suzhou Zelgen Biopharmaceuticals Co Ltd working capital to net assets ratio by year from 2016 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Suzhou Zelgen Biopharmaceuticals Co Ltd from 2016 to 2024, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 688266 total assets.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 96.0% | CN¥1.20 Billion | CN¥1.25 Billion | CN¥2.58 Billion | CN¥1.37 Billion | ▲ +11.8 pp |
| 2023 | 84.2% | CN¥1.39 Billion | CN¥1.64 Billion | CN¥2.52 Billion | CN¥1.14 Billion | ▲ +12.8 pp |
| 2022 | 71.4% | CN¥562.57 Million | CN¥787.49 Million | CN¥1.29 Billion | CN¥729.19 Million | ▼ -10.4 pp |
| 2021 | 81.8% | CN¥1.03 Billion | CN¥1.25 Billion | CN¥1.41 Billion | CN¥380.89 Million | ▼ -8.6 pp |
| 2020 | 90.4% | CN¥1.53 Billion | CN¥1.69 Billion | CN¥1.67 Billion | CN¥140.88 Million | ▲ +155.9 pp |
| 2019 | -65.6% | CN¥-48.34 Million | CN¥73.75 Million | CN¥101.82 Million | CN¥150.17 Million | ▼ -119.6 pp |
| 2018 | 54.0% | CN¥152.12 Million | CN¥281.64 Million | CN¥229.67 Million | CN¥77.56 Million | ▲ +50.9 pp |
| 2017 | 3.1% | CN¥2.26 Million | CN¥73.02 Million | CN¥71.64 Million | CN¥69.38 Million | ▼ -59.9 pp |
| 2016 | 63.0% | CN¥68.90 Million | CN¥109.44 Million | CN¥80.92 Million | CN¥12.02 Million | — |